Genprex, Inc. financial data

Symbol
GNPX on Nasdaq
Industry
Pharmaceutical Preparations
Location
1601 Trinity Street, Bldg. B, Suite 3.322, Austin, TX
State of incorporation
TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 13, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 200 % -52.6%
Return On Equity -409 % -112%
Return On Assets -269 % -73.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8.51M shares -85.7%
Common Stock, Shares, Outstanding 5.49M shares -90.8%
Entity Public Float 48.5M USD -26.5%
Common Stock, Value, Issued 5.49K USD -90.8%
Weighted Average Number of Shares Outstanding, Basic 3.5M shares +142%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 11.4M USD -34%
General and Administrative Expense 11.4M USD -20.6%
Costs and Expenses 22.8M USD -27.9%
Operating Income (Loss) -22.8M USD +27.9%
Net Income (Loss) Attributable to Parent -22.7M USD +27.8%
Earnings Per Share, Basic -11.5 USD/shares +69.9%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 1.49M USD -87.3%
Accounts Receivable, after Allowance for Credit Loss, Current 0 USD
Assets, Current 1.92M USD -85.1%
Property, Plant and Equipment, Net 463 USD -96%
Intangible Assets, Net (Excluding Goodwill) 0 USD -100%
Other Assets, Noncurrent 1.99M USD -47.3%
Assets 3.91M USD -76.5%
Liabilities, Current 2.24M USD -48.3%
Retained Earnings (Accumulated Deficit) -150M USD -17.8%
Stockholders' Equity Attributable to Parent 1.66M USD -86.5%
Liabilities and Equity 3.91M USD -76.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -5.3M USD +23.6%
Net Cash Provided by (Used in) Financing Activities 6.79M USD +66.5%
Net Cash Provided by (Used in) Investing Activities -15.8K USD +19.4%
Common Stock, Shares Authorized 200M shares 0%
Common Stock, Shares, Issued 5.49M shares -90.8%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 1.48M USD
Deferred Tax Assets, Valuation Allowance 23.4M USD +36.8%
Deferred Tax Assets, Gross 24.1M USD +34.9%
Depreciation 9.66K USD -45.3%
Deferred Tax Assets, Operating Loss Carryforwards 16.9M USD +16.9%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 152M USD +8.66%
Preferred Stock, Shares Outstanding 0 shares
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%